Patents by Inventor Søren Berg Padkær
Søren Berg Padkær has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20190248896Abstract: Described herein are anti-NKG2A antibodies suitable for human therapy, including humanized versions of murine anti-NKG2A antibody Z270, as well as related methods and materials for producing and using such antibodies. Exemplary complementarity-determining regions (CDRs) sequences and sites for optional amino acid back-substitutions in framework region (FR) and/or CDRs of such antibodies are also described.Type: ApplicationFiled: April 29, 2019Publication date: August 15, 2019Inventors: Petrus Johannes Louis Spee, Soeren Berg Padkaer
-
Publication number: 20170281809Abstract: Described herein are anti-NKG2A antibodies suitable for human therapy, including humanized versions of murine anti-NKG2A antibody Z270, as well as related methods and materials for producing and using such antibodies. Exemplary complementarity-determining regions (CDRs) sequences and sites for optional amino acid back-substitutions in framework region (FR) and/or CDRs of such antibodies are also described.Type: ApplicationFiled: June 16, 2017Publication date: October 5, 2017Inventors: PETRUS JOHANNES LOUIS SPEE, SOEREN BERG PADKAER
-
Patent number: 9708403Abstract: The present invention relates to agents and methods that are capable of augmenting NK-mediated killing of target cells by reducing inhibitory KIR signalling without reducing the binding of KIR to HLA-C. As described herein, transduction of negative signaling via KIR, upon binding of KIR to its HLA class I ligand, can involve a ligand-binding induced, conformational reorientation of the KIR molecules allowing interactions to form between adjacent KIRs in specific domains, leading to accelerated clustering. Methods and agents such as monoclonal antibodies for reducing KIR-mediated inhibition of NK cell cytotoxicity without reducing or blocking HLA-binding by, e.g., reducing or blocking dimerization of KIR, are provided.Type: GrantFiled: March 23, 2015Date of Patent: July 18, 2017Assignees: NOVO NORDISK A/S, INNATE PHARMAInventors: Søren Berg Padkær, Peter Andreas Nicolai Reumert Wagtmann, Petrus Johannes Louis Spee, Stefan Zahn, Kristian Kjærgaard, Anders Svensson
-
Patent number: 9683041Abstract: Described herein are anti-NKG2A antibodies suitable for human therapy, including humanized versions of murine anti-NKG2A antibody Z270, as well as related methods and materials for producing and using such antibodies. Exemplary complementarity-determining regions (CDRs) sequences and sites for optional amino acid back-substitutions in framework region (FR) and/or CDRs of such antibodies are also described.Type: GrantFiled: November 20, 2014Date of Patent: June 20, 2017Assignee: NOVO NORDISK A/SInventors: Petrus Johannes Louis Spee, Soeren Berg Padkaer
-
Publication number: 20160046712Abstract: The present invention relates to agents and methods that are capable of augmenting NK-mediated killing of target cells by reducing inhibitory KIR signalling without reducing the binding of KIR to HLA-C. As described herein, transduction of negative signaling via KIR, upon binding of KIR to its HLA class I ligand, can involve a ligand-binding induced, conformational reorientation of the KIR molecules allowing interactions to form between adjacent KIRs in specific domains, leading to accelerated clustering. Methods and agents such as monoclonal antibodies for reducing KIR-mediated inhibition of NK cell cytotoxicity without reducing or blocking HLA-binding by, e.g., reducing or blocking dimerization of KIR, are provided.Type: ApplicationFiled: March 23, 2015Publication date: February 18, 2016Inventors: Søren Berg Padkær, Peter Andreas, Nicolai, Reumert Wagtmann, Pieter Spee, Stefan Zahn, Kristian Kjærgaard, Anders Svensson
-
Patent number: 9018366Abstract: The present invention relates to agents and methods that are capable of augmenting NK-mediated killing of target cells by reducing inhibitory KIR signalling without reducing the binding of KIR to HLA-C. As described herein, transduction of negative signaling via KIR, upon binding of KIR to its HLA class I ligand, can involve a ligand-binding induced, conformational reorientation of the KIR molecules allowing interactions to form between adjacent KIRs in specific domains, leading to accelerated clustering. Methods and agents such as monoclonal antibodies for reducing KIR-mediated inhibition of NK cell cytotoxicity without reducing or blocking HLA-binding by, e.g., reducing or blocking dimerization of KIR, are provided.Type: GrantFiled: January 18, 2013Date of Patent: April 28, 2015Assignees: Innate Pharma S.A.S, Novo Nordisk A/SInventors: Søren Berg Padkær, Peter Andreas Nicolai Reumert Wagtmann, Pieter Spee, Stefan Zahn, Kristian Kjærgaard, Anders Svensson
-
Publication number: 20150071929Abstract: Described herein are anti-NKG2A antibodies suitable for human therapy, including humanized versions of murine anti-NKG2A antibody Z270, as well as related methods and materials for producing and using such antibodies. Exemplary complementarity-determining regions (CDRs) sequences and sites for optional amino acid back-substitutions in framework region (FR) and/or CDRs of such antibodies are also described.Type: ApplicationFiled: November 20, 2014Publication date: March 12, 2015Inventors: PETRUS JOHANNES LOUIS SPEE, SOEREN BERG PADKAER
-
Patent number: 8901283Abstract: Described herein are anti-NKG2A antibodies suitable for human therapy, including humanized versions of murine anti-NKG2A antibody Z270, as well as related methods and materials for producing and using such antibodies. Exemplary complementarity-determining regions (CDRs) sequences and sites for optional amino acid back-substitutions in framework region (FR) and/or CDRs of such antibodies are also described.Type: GrantFiled: May 22, 2012Date of Patent: December 2, 2014Assignee: Novo Nordisk A/SInventors: Petrus Johannes Louis Spee, Soeren Berg Padkaer
-
Patent number: 8388970Abstract: The present invention relates to agents and methods that are capable of augmenting NK-mediated killing of target cells by reducing inhibitory KIR signalling without reducing the binding of KIR to HLA-C. As described herein, transduction of negative signaling via KIR, upon binding of KIR to its HLA class I ligand, can involve a ligand-binding induced, conformational reorientation of the KIR molecules allowing interactions to form between adjacent KIRs in specific domains, leading to accelerated clustering. Methods and agents such as monoclonal antibodies for reducing KIR-mediated inhibition of NK cell cytotoxicity without reducing or blocking HLA-binding by, e.g., reducing or blocking dimerization of KIR, are provided.Type: GrantFiled: October 2, 2008Date of Patent: March 5, 2013Assignees: Novo Nordisk A/S, Innate Pharma S.A.S.Inventors: Søren Berg Padkær, Peter Andreas Nicolai Reumert Wagtmann, Pieter Spee, Stefan Zahn, Kristian Kjærgaard, Anders Svensson
-
Publication number: 20120237510Abstract: Described herein are anti-NKG2A antibodies suitable for human therapy, including humanized versions of murine anti-NKG2A antibody Z270, as well as related methods and materials for producing and using such antibodies. Exemplary complementarity-determining regions (CDRs) sequences and sites for optional amino acid back-substitutions in framework region (FR) and/or CDRs of such antibodies are also described.Type: ApplicationFiled: May 22, 2012Publication date: September 20, 2012Applicant: Novo Nordisk A/SInventors: Petrus Johannes Louis Spee, Søren Berg Padkær
-
Publication number: 20120208237Abstract: Compositions and methods for regulating an immune response in a subject are described. More particularly, described are human antibodies that regulate the activity of NK cells and allow a potentiation of NK cell cytotoxicity in mammalian subjects, and antibodies having antigen-binding properties similar to those of human monoclonal antibody 1-7F9 or 1-4F1. Described also are also fragments and derivatives of such antibodies, as well as pharmaceutical compositions comprising the same and their uses, particularly for use in therapy, to increase NK cell activity or cytotoxicity in subjects.Type: ApplicationFiled: January 11, 2012Publication date: August 16, 2012Applicants: Innate Pharma S.A.S, Novo-Nordisk A/S - Novo AlleInventors: Alessandro Moretta, Mariella Della Chiesa, Pascale Andre, Laurent Gauthier, Francois Romagné, Peter Andreas Nicolai Reumert Wagtmann, Ivan Svendsen, Stefan Zahn, Anders Svensson, Matthias Thórólfsson, Søren Berg Padkær, Kristian Kjaergaard, Pieter Spee, Michael Wilken
-
Patent number: 8222376Abstract: The present invention relates to agents and methods that are capable of augmenting NK-mediated killing of target cells by reducing inhibitory KIR signalling without reducing the binding of KIR to HLA-C. As described herein, transduction of negative signaling via KIR, 5 upon binding of KIR to its HLA class I ligand, can involve a ligand-binding induced, conformational reorientation of the KIR molecules allowing interactions to form between adjacent KIRs in specific domains, leading to accelerated clustering. Methods and agents such as mono-clonal antibodies for reducing KIR-mediated inhibition of NK cell cytotoxicity without reducing or blocking HLA-binding by, e.g., reducing or blocking dimerization of KIR, are provided.Type: GrantFiled: January 6, 2006Date of Patent: July 17, 2012Assignees: Novo Nordisk A/S, Inmate Pharma S.A.S.Inventors: Søren Berg Padkær, Peter Reumert Wagtmann, Pieter Spee, Stefan Zahn, Kristian Kjærgaard
-
Patent number: 8206709Abstract: Described herein are anti-NKG2A antibodies suitable for human therapy, including humanized versions of murine anti-NKG2A antibody Z270, as well as related methods and materials for producing and using such antibodies. Exemplary complementarity-determining regions (CDRs) sequences and sites for optional amino acid back-substitutions in framework region (FR) and/or CDRs of such antibodies are also described.Type: GrantFiled: June 28, 2007Date of Patent: June 26, 2012Assignee: Novo Nordisk A/SInventors: Petrus Johannes Louis Spee, Søren Berg Padkær
-
Patent number: 8119775Abstract: Compositions and methods for regulating an immune response in a subject are described. More particularly, described are human antibodies that regulate the activity of NK cells and allow a potentiation of NK cell cytotoxicity in mammalian subjects, and antibodies having antigen-binding properties similar to those of human monoclonal antibody 1-7F9 or 1-4F1. Described also are also fragments and derivatives of such antibodies, as well as pharmaceutical compositions comprising the same and their uses, particularly for use in therapy, to increase NK cell activity or cytotoxicity in subjects.Type: GrantFiled: October 2, 2008Date of Patent: February 21, 2012Assignees: University of Genoa, Innate Pharma S.A.S., Novo Nordisk A/SInventors: Alessandro Moretta, Mariella Della Chiesa, Pascale Andre, Laurent Gauthier, Francois Romagné, Peter Andreas Nicolai Reumert Wagtmann, Ivan Svendsen, Stefan Zahn, Anders Svensson, Matthias Thórólfsson, Søren Berg Padkær, Kristian Kjaergaard, Pieter Spee, Michael Wilken
-
Patent number: 7932055Abstract: Soluble versions of heterodimeric receptors, e.g., CD94/NKG2 receptors, and methods of producing and using such constructs, are described. The constructs comprise soluble fragments of, each receptor monomer, and some constructs further comprise at least one immunoglobulin Fc domain. Exemplary constructs are those wherein (1) each soluble fragment is linked to an immunoglobulin Fc domain, which are then allowed to dimerize, (2) each soluble fragment is linked to an immunoglobulin Fc domain mutated to promote forced dimerization with the correct counterpart, and (3) single-chain constructs where the monomeric receptor fragments are linked, and the C-terminal fragment is linked to an Fc domain.Type: GrantFiled: June 22, 2007Date of Patent: April 26, 2011Assignee: Novo Nordisk A/SInventors: Petrus Johannes Louis Spee, Søren Berg Padkær, Birgitte Nissen Friedrichsen, Inga Sig Nielsen Nørby
-
Publication number: 20100247526Abstract: Described herein are anti-NKG2A antibodies suitable for human therapy, including humanized versions of murine anti-NKG2A antibody Z270, as well as related methods and materials for producing and using such antibodies. Exemplary complementarity-determining regions (CDRs) sequences and sites for optional amino acid back-substitutions in framework region (FR) and/or CDRs of such antibodies are also described.Type: ApplicationFiled: June 28, 2007Publication date: September 30, 2010Applicant: Novo Nordisk A/SInventors: Petrus Johannes Louis Spee, Søren Berg Padkær